Tardive Dyskinesia: Unmasking the Consequence of Antipsychotic Medications

QUESTION

A patient presents to the psychiatry department with a history of use of antipsychotics. He experienced hyperkinetic jerky movements in the whole body when he tried to shift on low potency antipsychotics. What is the most likely diagnosis?

ANSWER

Tardive Dyskinesia: Unmasking the Consequence of Antipsychotic Medications

Introduction

The use of antipsychotic medications is a common and often essential component of managing various psychiatric disorders, such as schizophrenia and bipolar disorder. However, their usage is not without potential side effects, some of which can be severe and long-lasting. In this essay, we will explore a patient’s presentation to the psychiatry department with a history of antipsychotic use and the likely diagnosis of tardive dyskinesia, a movement disorder associated with antipsychotic medications.

Tardive Dyskinesia: An Overview

Tardive dyskinesia (TD) is a neurological disorder characterized by hyperkinetic, involuntary, and repetitive movements of various muscle groups, often involving the face, limbs, and trunk. These movements can manifest as choreiform (jerky), dystonic (sustained), or athetoid (writhing) and typically persist even when the patient is not taking antipsychotic medications (Caroff, 2014).

Likely Diagnosis

In the case presented, the patient’s history of using low-potency antipsychotics and the manifestation of hyperkinetic jerky movements when trying to shift strongly point towards a likely diagnosis of tardive dyskinesia. TD is a well-recognized side effect of antipsychotic medications, especially the first-generation or typical antipsychotics, which include drugs like haloperidol and chlorpromazine (Caroff, 2014).

Pathophysiology and Risk Factors

The exact pathophysiology of TD is not entirely understood, but it is believed to involve alterations in dopamine receptor sensitivity in the basal ganglia, a brain region responsible for motor control (Carbon & Hsieh, 2017). Risk factors for TD development include prolonged antipsychotic use, higher cumulative antipsychotic dosage, and older age. Additionally, low-potency antipsychotics, like those mentioned in the case, have been associated with a higher risk of TD (Caroff, 2014).

Management and Implications

TD can significantly impact a patient’s quality of life, and its management typically involves discontinuing or reducing the offending antipsychotic medication, if clinically feasible. However, this decision should be made carefully, balancing the risks of TD with the need for ongoing psychiatric treatment. Second-generation or atypical antipsychotics are often preferred, as they have a lower risk of TD (Carbon & Hsieh, 2017).

Conclusion

The presentation of hyperkinetic jerky movements in a patient with a history of low-potency antipsychotic use strongly suggests the diagnosis of tardive dyskinesia. This movement disorder is an important consideration when using antipsychotic medications, emphasizing the need for regular monitoring of patients for signs and symptoms of TD. Identifying and managing TD is crucial for improving the quality of life for individuals with psychiatric disorders while minimizing the risk of debilitating side effects associated with antipsychotic use.